Tumour-targeting bacteria engineered to fight cancer

Shibin Zhou, Claudia Gravekamp, David Bermudes, Ke Liu

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.

Original languageEnglish (US)
Pages (from-to)727-743
Number of pages17
JournalNature Reviews Cancer
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Bacteria
Neoplasms
Therapeutics
Bioengineering
Robotics
Adaptive Immunity
Antineoplastic Agents
Immunotherapy
Clinical Trials
Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumour-targeting bacteria engineered to fight cancer. / Zhou, Shibin; Gravekamp, Claudia; Bermudes, David; Liu, Ke.

In: Nature Reviews Cancer, Vol. 18, No. 12, 01.12.2018, p. 727-743.

Research output: Contribution to journalReview article

Zhou, Shibin ; Gravekamp, Claudia ; Bermudes, David ; Liu, Ke. / Tumour-targeting bacteria engineered to fight cancer. In: Nature Reviews Cancer. 2018 ; Vol. 18, No. 12. pp. 727-743.
@article{b96a3c1d78964439bb0a072a3f4e4fc8,
title = "Tumour-targeting bacteria engineered to fight cancer",
abstract = "Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.",
author = "Shibin Zhou and Claudia Gravekamp and David Bermudes and Ke Liu",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41568-018-0070-z",
language = "English (US)",
volume = "18",
pages = "727--743",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Tumour-targeting bacteria engineered to fight cancer

AU - Zhou, Shibin

AU - Gravekamp, Claudia

AU - Bermudes, David

AU - Liu, Ke

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.

AB - Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.

UR - http://www.scopus.com/inward/record.url?scp=85056343066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056343066&partnerID=8YFLogxK

U2 - 10.1038/s41568-018-0070-z

DO - 10.1038/s41568-018-0070-z

M3 - Review article

VL - 18

SP - 727

EP - 743

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 12

ER -